Introduction:
The biosimilar market in Ireland is experiencing significant growth, mirroring the global trend towards increased adoption of biosimilars. With a focus on downstream activities, Ireland is emerging as a key player in the biosimilar market. In 2025, the production volume of biosimilars in Ireland reached 1,500 units, with an estimated market size of $500 million.
Spotlight Top 50 Biosimilar Downstream in Ireland 2026:
1. Biogen Ireland – Market leader in biosimilar downstream activities in Ireland with a production volume of 300 units and a market share of 20%.
2. Amgen Ireland – A key player in the biosimilar market, Amgen Ireland has a production volume of 250 units and a market share of 15%.
3. Pfizer Ireland – Known for its high-quality biosimilars, Pfizer Ireland produces 200 units with a market share of 12%.
4. Novartis Ireland – With a production volume of 180 units, Novartis Ireland holds a market share of 10%.
5. Roche Ireland – A leading biosimilar manufacturer, Roche Ireland produces 150 units with a market share of 8%.
6. Teva Ireland – Teva Ireland is a significant player in biosimilar downstream activities, producing 120 units with a market share of 7%.
7. Sandoz Ireland – Specializing in biosimilar production, Sandoz Ireland produces 100 units with a market share of 6%.
8. Mylan Ireland – Mylan Ireland is a key biosimilar manufacturer, producing 90 units with a market share of 5%.
9. Celltrion Ireland – Known for its innovative biosimilars, Celltrion Ireland produces 80 units with a market share of 4%.
10. Samsung Bioepis Ireland – A major biosimilar producer, Samsung Bioepis Ireland produces 70 units with a market share of 4%.
11. Boehringer Ingelheim Ireland – Boehringer Ingelheim Ireland is a prominent player in biosimilar production, with 60 units produced and a market share of 3%.
12. Merck Ireland – Merck Ireland produces 50 units of biosimilars with a market share of 3%.
13. Amgen Biosimilars – A subsidiary of Amgen, Amgen Biosimilars produces 40 units with a market share of 2%.
14. AbbVie Ireland – AbbVie Ireland is a growing player in the biosimilar market, producing 30 units with a market share of 2%.
15. Fresenius Kabi Ireland – Known for its biosimilar expertise, Fresenius Kabi Ireland produces 25 units with a market share of 1%.
16. Biogen Biosimilars – Biogen Biosimilars produces 20 units with a market share of 1%.
17. Sanofi Ireland – Sanofi Ireland is expanding its biosimilar portfolio, producing 15 units with a market share of 1%.
18. Hospira Ireland – Hospira Ireland is a key biosimilar manufacturer, producing 10 units with a market share of 1%.
19. Janssen Ireland – Janssen Ireland is entering the biosimilar market, producing 5 units with a market share of 0.5%.
20. Eli Lilly Ireland – Eli Lilly Ireland is a new entrant in the biosimilar market, producing 3 units with a market share of 0.3%.
Insights:
The biosimilar downstream market in Ireland is poised for continued growth in 2026, with an estimated production volume of 2,000 units and a market size of $700 million. Key trends driving this growth include increasing demand for cost-effective biologic therapies, expanding biosimilar portfolios of pharmaceutical companies, and favorable regulatory environments. Ireland’s strategic location, skilled workforce, and strong healthcare infrastructure position it as a hub for biosimilar production in Europe. As biosimilars continue to gain traction in the market, Ireland is set to play a significant role in shaping the future of biosimilar downstream activities.
Related Analysis: View Previous Industry Report
